Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis.

Fischer R, Padutsch T, Bracchi-Ricard V, Murphy KL, Martinez GF, Delguercio N, Elmer N, Sendetski M, Diem R, Eisel ULM, Smeyne RJ, Kontermann RE, Pfizenmaier K, Bethea JR.

Brain Behav Immun. 2019 Jun 17. pii: S0889-1591(19)30378-2. doi: 10.1016/j.bbi.2019.06.021. [Epub ahead of print]

PMID:
31220564
2.

Calcium-Binding Proteins as Determinants of Central Nervous System Neuronal Vulnerability to Disease.

Fairless R, Williams SK, Diem R.

Int J Mol Sci. 2019 Apr 30;20(9). pii: E2146. doi: 10.3390/ijms20092146. Review.

3.

Preclinical stress originates in the rat optic nerve head during development of autoimmune optic neuritis.

Stojic A, Bojcevski J, Williams SK, Bas-Orth C, Nessler S, Linington C, Diem R, Fairless R.

Glia. 2019 Mar;67(3):512-524. doi: 10.1002/glia.23560. Epub 2018 Dec 21.

4.

Steroid-Responsive Relapsing-Remitting Neutrophilic Encephalitis: A Case Report.

Ungerer MN, Diem R, Wrede A, Huang K, Hähnel S, Wick W, Winkler F.

J Neuropathol Exp Neurol. 2018 Nov 1;77(11):993-996. doi: 10.1093/jnen/nly088.

PMID:
30299484
5.

Early auto-immune targeting of photoreceptor ribbon synapses in mouse models of multiple sclerosis.

Dembla M, Kesharwani A, Natarajan S, Fecher-Trost C, Fairless R, Williams SK, Flockerzi V, Diem R, Schwarz K, Schmitz F.

EMBO Mol Med. 2018 Nov;10(11). pii: e8926. doi: 10.15252/emmm.201808926.

6.

Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis.

Williams SK, Fairless R, Maier O, Liermann PC, Pichi K, Fischer R, Eisel ULM, Kontermann R, Herrmann A, Weksler B, Romero N, Couraud PO, Pfizenmaier K, Diem R.

Sci Rep. 2018 Sep 11;8(1):13628. doi: 10.1038/s41598-018-31957-7.

7.

Selective Vulnerability of αOFF Retinal Ganglion Cells during Onset of Autoimmune Optic Neuritis.

Mayer C, Bruehl C, Salt EL, Diem R, Draguhn A, Fairless R.

Neuroscience. 2018 Nov 21;393:258-272. doi: 10.1016/j.neuroscience.2018.07.040. Epub 2018 Aug 1.

PMID:
30075244
8.

Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI.

Karimian-Jazi K, Wildemann B, Diem R, Schwarz D, Hielscher T, Wick W, Bendszus M, Breckwoldt MO.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 16;5(5):e480. doi: 10.1212/NXI.0000000000000480. eCollection 2018 Sep.

9.

Early Nodal and Paranodal Disruption in Autoimmune Optic Neuritis.

Stojic A, Bojcevski J, Williams SK, Diem R, Fairless R.

J Neuropathol Exp Neurol. 2018 May 1;77(5):361-373. doi: 10.1093/jnen/nly011.

PMID:
29444299
10.

Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography.

Jende JME, Hauck GH, Diem R, Weiler M, Heiland S, Wildemann B, Korporal-Kuhnke M, Wick W, Hayes JM, Pfaff J, Pham M, Bendszus M, Kollmer J.

Ann Neurol. 2017 Nov;82(5):676-685. doi: 10.1002/ana.25068. Epub 2017 Oct 26.

11.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
12.

Failure of alemtuzumab therapy to control MOG encephalomyelitis.

Wildemann B, Jarius S, Schwarz A, Diem R, Viehöver A, Hähnel S, Reindl M, Korporal-Kuhnke M.

Neurology. 2017 Jul 11;89(2):207-209. doi: 10.1212/WNL.0000000000004087. Epub 2017 Jun 9. No abstract available.

PMID:
28600462
13.

Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.

Lanz TV, Williams SK, Stojic A, Iwantscheff S, Sonner JK, Grabitz C, Becker S, Böhler LI, Mohapatra SR, Sahm F, Küblbeck G, Nakamura T, Funakoshi H, Opitz CA, Wick W, Diem R, Platten M.

Sci Rep. 2017 Jan 24;7:41271. doi: 10.1038/srep41271.

14.

Murine Autoimmune Optic Neuritis Is Not Phenotypically Altered by the Retinal Degeneration 8 Mutation.

Stojic A, Fairless R, Beck SC, Sothilingam V, Weissgerber P, Wissenbach U, Gimmy V, Seeliger MW, Flockerzi V, Diem R, Williams SK.

Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):318-328. doi: 10.1167/iovs.16-20419.

PMID:
28114593
15.

Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.

Breckwoldt MO, Gradl J, Hähnel S, Hielscher T, Wildemann B, Diem R, Platten M, Wick W, Heiland S, Bendszus M.

J Neurol. 2017 Feb;264(2):341-349. doi: 10.1007/s00415-016-8353-3. Epub 2016 Dec 1.

PMID:
27909801
16.

Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin.

Sühs KW, Papanagiotou P, Hein K, Pul R, Scholz K, Heesen C, Diem R.

Int J Mol Sci. 2016 Sep 30;17(10). pii: E1666.

17.

Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.

Obert D, Helms G, Sättler MB, Jung K, Kretzschmar B, Bähr M, Dechent P, Diem R, Hein K.

PLoS One. 2016 Sep 16;11(9):e0162583. doi: 10.1371/journal.pone.0162583. eCollection 2016.

18.

Sodium MRI in Multiple Sclerosis is Compatible with Intracellular Sodium Accumulation and Inflammation-Induced Hyper-Cellularity of Acute Brain Lesions.

Biller A, Pflugmann I, Badde S, Diem R, Wildemann B, Nagel AM, Jordan J, Benkhedah N, Kleesiek J.

Sci Rep. 2016 Aug 10;6:31269. doi: 10.1038/srep31269.

19.

Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.

Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich SP, Joachimsen L, Rauer S, Pielen A, Sühs KW, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Tonagel F, Kernstock C, Hartmann K, Kümpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Müller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagrèze WA.

BMJ Open. 2016 Mar 1;6(3):e010956. doi: 10.1136/bmjopen-2015-010956.

20.

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators.

Neurology. 2015 Mar 17;84(11):1145-52. doi: 10.1212/WNL.0000000000001360. Epub 2015 Feb 13.

Supplemental Content

Loading ...
Support Center